Jeff Yass’s Albany Molecular Research Inc AMRI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q3 | – | Sell |
-63,500
| Closed | -$1.38M | – | 10229 |
|
|
2017
Q2 | $1.38M | Sell |
63,500
-4,900
| -7% | -$88.9K | ﹤0.01% | 4610 |
|
|
2017
Q1 | $960K | Buy |
68,400
+8,500
| +14% | +$139K | ﹤0.01% | 5217 |
|
|
2016
Q4 | $1.12M | Buy |
59,900
+900
| +2% | +$15.3K | ﹤0.01% | 5272 |
|
|
2016
Q3 | $974K | Buy |
59,000
+42,900
| +266% | +$636K | ﹤0.01% | 4858 |
|
|
2016
Q2 | $216K | Buy |
+16,100
| New | +$235K | ﹤0.01% | 7487 |
|
|
2016
Q1 | – | Sell |
-16,400
| Closed | -$326K | – | 10145 |
|
|
2015
Q4 | $326K | Sell |
16,400
-45,400
| -73% | -$863K | ﹤0.01% | 7525 |
|
|
2015
Q3 | $1.08M | Sell |
61,800
-32,100
| -34% | -$654K | ﹤0.01% | 5598 |
|
|
2015
Q2 | $1.9M | Buy |
93,900
+68,200
| +265% | +$1.32M | ﹤0.01% | 4828 |
|
|
2015
Q1 | $452K | Sell |
25,700
-23,000
| -47% | -$392K | ﹤0.01% | 7276 |
|
|
2014
Q4 | $793K | Buy |
48,700
+32,100
| +193% | +$589K | ﹤0.01% | 6321 |
|
|
2014
Q3 | $366K | Sell |
16,600
-59,600
| -78% | -$1.22M | ﹤0.01% | 7732 |
|
|
2014
Q2 | $1.53M | Sell |
76,200
-40,100
| -34% | -$679K | ﹤0.01% | 5180 |
|
|
2014
Q1 | $2.16M | Sell |
116,300
-5,700
| -5% | -$78.5K | ﹤0.01% | 4211 |
|
|
2013
Q4 | $1.23M | Buy |
122,000
+83,100
| +214% | +$1M | ﹤0.01% | 5133 |
|
|
2013
Q3 | $501K | Buy |
38,900
+14,300
| +58% | +$176K | ﹤0.01% | 6420 |
|
|
2013
Q2 | $292K | Buy |
+24,600
| New | +$266K | ﹤0.01% | 6851 |
|
Other funds holding AMRI
Jeff Yass's AMRI Position: Q2 2015 in Review
Jeff Yass sold out of Albany Molecular Research Inc (AMRI) in Q2 2015, closing a stake of 48,841 shares — an estimated $943K sold.
Jeff Yass first reported a position in AMRI in Q4 2013 and held it in 2 quarters. The position peaked at $860K in Q1 2015. 131 funds tracked by Wall St. Rank hold AMRI as of Q2 2015.
- Jeff Yass reported no remaining Albany Molecular Research Inc position as of Q2 2015 after selling out during the quarter.
- Jeff Yass sold 48,841 Albany Molecular Research Inc shares in Q2 2015, an estimated $943K.
- Jeff Yass first reported a position in Albany Molecular Research Inc in Q4 2013 and held it in 2 quarters.
- Jeff Yass's Albany Molecular Research Inc position peaked at $860K in Q1 2015.
- 131 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q2 2015.
Based on Susquehanna International Group's 13F filing for Q2 2015, filed 14 Aug 2015.